Femasys (NASDAQ:FEMY) Earns “Buy” Rating from HC Wainwright

Femasys (NASDAQ:FEMY)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They currently have a $12.00 price target on the stock.

Separately, Chardan Capital reduced their price objective on Femasys from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, August 14th.

Femasys Stock Down 5.3 %

Shares of NASDAQ:FEMY opened at $1.26 on Thursday. The company has a quick ratio of 5.93, a current ratio of 6.47 and a debt-to-equity ratio of 0.43. Femasys has a 52-week low of $0.73 and a 52-week high of $2.40. The stock’s fifty day simple moving average is $1.16 and its 200-day simple moving average is $1.16. The company has a market capitalization of $28.01 million, a P/E ratio of -1.52 and a beta of -2.82.

Femasys (NASDAQ:FEMY) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.03). Femasys had a negative net margin of 1,757.16% and a negative return on equity of 119.97%. The company had revenue of $0.22 million during the quarter, compared to analysts’ expectations of $0.50 million. As a group, equities research analysts forecast that Femasys will post -0.79 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Femasys

A hedge fund recently raised its stake in Femasys stock. CM Management LLC boosted its holdings in Femasys Inc. (NASDAQ:FEMY) by 6.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 425,000 shares of the company’s stock after purchasing an additional 25,000 shares during the quarter. CM Management LLC owned approximately 1.91% of Femasys worth $484,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.